证券代码：833230 证券简称：欧康医药 公告编号：2023-070 成都欧康医药股份有限公司 关于公司食品生产许可证变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 成都欧康医药股份有限公司（以下简称"公司"）于近日取得成都市市场监 督管理局颁发的《食品生产许可证》，同意公司《食品生产许可证》的变更申请。 本次变更主要涉及新增 5 个产品的生产，其他内容不变。具体情况如下： 一、变更后的《食品生产许可证》基本情况 生产者名称：成都欧康医药股份有限公司 统一社会信用代码：91510100698888960C 法定代表人（负责人）：赵卓君 住所：邛崃市临邛工业园区创业路 15 号 生产地址：邛崃市临邛工业园区创业路 15 号 食品类别：食品添加剂，蛋制品 许可证编号：SC20151018350046 有效期至：2028 年 9 月 13 日 发证机关：成都市市场监督管理局 二、对公司的影响 本次变更《食品生产许可证》是在原有的"新甲基橙皮苷二氢查耳酮、柚苷、 L-鼠李糖"3 个食品添加剂类产品 ...

成都欧康医药股份有限公司 关于分公司完成工商登记并取得营业执照的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：833230 证券简称：欧康医药 公告编号：2023-069 1、名称：成都欧康医药股份有限公司羟基芦丁分公司 证件为准） 一般项目：食品添加剂销售；专用化学产品销售（不含危险化学 品）；医学研究和试验发展；信息咨询服务（不含许可类信息咨询服务）；技术服 务、技术开发、技术咨询、技术交流、技术转让、技术推广；技术进出口；货物 进出口；农业科学研究和试验发展。（除依法须批准的项目外，凭营业执照依法 自主开展经营活动） 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日召开 第三届董事会第二十次会议，审议通过了《关于设立分公司的议案》。公司于 2023 年 8 月 22 日在北京证券交易所网站（www.bse.cn）进行了披露。详见《成都欧 康医药股份有限公司第三届董事会第二十次会议决议公告》（公告编号：2023- 064）、《成都欧康医药 ...

Financial Performance - In the first half of 2023, the company's operating revenue was ¥112,225,810.15, a decrease of 27.01% compared to ¥153,751,776.79 in the same period last year[27]. - The gross profit margin for the first half of 2023 was 18.13%, down from 28.18% in the previous year[27]. - The net profit attributable to shareholders of the listed company was ¥10,245,890.81, representing a decline of 60.98% from ¥26,257,163.71 in the same period last year[27]. - The net profit after deducting non-recurring gains and losses was ¥8,889,919.72, down 64.40% from ¥24,973,970.37 year-on-year[27]. - The weighted average return on net assets based on net profit attributable to shareholders was 2.61%, a decrease from 16.72% in the previous year[27]. - Operating cash flow decreased by 26.90% to ¥32,148,479.36 from ¥43,976,719.02 year-over-year[29]. - Net profit decreased by 60.98% compared to the same period last year[30]. - The company achieved a net non-recurring profit of ¥1,355,971.09 after tax[32]. - The company reported a 216.13% increase in revenue from rutin and a 178.89% increase in revenue from berberine, contributing to overall profit growth[41]. - The company’s external sales revenue grew by 6.39% year-on-year, while internal sales revenue fell by 35.86%[66]. Assets and Liabilities - Total assets decreased by 3.23% to ¥426,252,902.73 from ¥440,473,318.89 year-over-year[28]. - Total liabilities decreased by 18.96% to ¥40,703,541.34 from ¥50,225,567.49 year-over-year[28]. - The company's cash and cash equivalents decreased by 38.52% to 118,479,830.62 CNY, primarily due to cash payments for project construction and bank loan repayments[54]. - Accounts receivable decreased by 39.67% to 36,407,318.76 CNY, attributed to improved customer credit management strategies[54]. - The company's construction in progress increased by 308.25% to 51,234,431.25 CNY, reflecting significant investment in project upgrades and expansions[54]. - The total current assets decreased from CNY 378,983,354.45 as of December 31, 2022, to CNY 320,567,537.36 as of June 30, 2023, representing a decline of approximately 15.4%[120]. - The total non-current assets increased from CNY 61,489,964.44 as of December 31, 2022, to CNY 105,685,365.37 as of June 30, 2023, indicating an increase of approximately 71.8%[122]. - The total liabilities decreased from CNY 50,225,567.49 as of December 31, 2022, to CNY 40,703,541.34 as of June 30, 2023, reflecting a reduction of about 19.0%[123]. Investments and Fundraising - The company is actively advancing its fundraising projects, with the "Chengdu Okay Pharmaceutical Co., Ltd. Technical Transformation and Expansion Project (Phase I)" progressing smoothly according to plan[7]. - The company has invested an additional ¥35 million in fundraising projects to improve product quality and production efficiency[36]. - The company raised a total of RMB 231,500,556.80 from the public offering of shares, with a net amount of RMB 212,317,682.73 after deducting issuance costs[105]. - As of June 30, 2023, the cumulative investment in fundraising projects amounted to RMB 135,762,100, with RMB 101,566,700 used during the reporting period[106]. - The balance of the fundraising account as of June 30, 2023, was RMB 79,961,000[106]. Research and Development - The company has obtained two invention patents, bringing the total number of patents to 36 as of the report date[5]. - The company has obtained two invention patents related to the preparation processes of flavonoids, enhancing its competitive edge in cost reduction and innovation[37]. - R&D expenses increased by 13.37% due to heightened investment in innovation, while management, financial, and sales expenses were reduced by 17.55%, 183.55%, and 5.79% respectively[44]. - The company is focusing on research and development of new products and improving production processes to enhance competitiveness[84]. Market Expansion and Strategy - The company established a foreign holding subsidiary, OKAYPHARM USA INC., in Los Angeles to expand into the health product market[8]. - The company plans to expand its product applications in domestic markets, including functional food ingredients and cosmetics, while also developing a health product brand in the U.S. using quercetin[43]. - The company is investing in an automated workshop and digital factory to enhance production efficiency and reduce costs for its products[42]. - The company is actively developing domestic raw materials and functional food markets to mitigate risks from international trade environments[80]. - The company is focused on expanding its market presence both domestically and internationally to achieve a dual-market strategy[80]. Compliance and Certifications - The company has passed multiple quality certifications including EuGMP, FSSC22000, HACCP22000, ISO9001, HALAL, and KOSHER, which are crucial for maintaining market access[80]. - The company has obtained the Pollution Discharge Permit from the Chengdu Ecological Environment Bureau, valid from December 22, 2020, to December 21, 2025[78]. - The company has established an EHS management system to oversee environmental protection and pollution control during production[78]. Shareholder Information - The total number of ordinary shares at the end of the period is 75,631,404, with 25% being unrestricted shares after the conversion of 3,202,320 restricted shares[99][100]. - Major shareholders include Zhao Zhuojun with 31,178,881 shares (41.22%) and Wu Li with 20,748,000 shares (27.43%) at the end of the reporting period[103]. - The total shares held by directors and supervisors amount to 53,370,830, which is 70.55% of the total shares[113]. - The company has not issued any preferred shares or convertible bonds during the reporting period[108]. Financial Management - The company has provided guarantees totaling ¥10,000,000 for loans at both Agricultural Bank of China and China Merchants Bank, with a guarantee period from February 2023 to February 2025[91]. - The company has also guaranteed ¥5,000,000 for a loan at Industrial and Commercial Bank of China, with a guarantee period from June 2023 to June 2024[91]. - The company has completed the repayment of all mortgage loans from Bank of China by June 30, 2023, although the asset release procedures are still pending[96]. Operational Changes - The company has established a comprehensive employee welfare system to ensure fair and healthy working conditions[77]. - The company appointed a new supervisor, Li Hua, due to the resignation of Wei Liuli, ensuring compliance with the legal minimum number of supervisory board members[115]. - The number of total employees increased from 208 at the beginning of the period to 210 at the end of the period, with a net addition of 2 employees[117]. - The number of technical personnel increased from 43 to 46, showing a growth of approximately 7.0%[117].

Financial Performance - Operating revenue for Q1 2023 was CNY 58,924,811.64, representing a year-on-year decline of 32.79%[11] - Net profit attributable to shareholders for Q1 2023 was CNY 5,623,307.50, down 63.17% from the same period last year[11] - The basic earnings per share for Q1 2023 was CNY 0.07, down 74.07% compared to the same period last year[12] - Gross profit for Q1 2023 was ¥10,723,546.57, down from ¥26,070,163.09 in Q1 2022, indicating a decrease of about 58.8%[45] - Net profit for Q1 2023 was ¥5,688,786.31, compared to ¥15,268,841.14 in Q1 2022, reflecting a decline of approximately 62.7%[46] - The total comprehensive income for Q1 2023 was ¥5,688,786.31, down from ¥15,268,841.14 in Q1 2022, reflecting a decrease of about 62.7%[47] Cash Flow and Assets - The company reported a net cash flow from operating activities of -CNY 19,892,433.69, a decrease of 166.96% compared to the previous year[11] - Cash and cash equivalents were reported at CNY 126,529,528.29, compared to CNY 192,703,332.20 in the previous period, representing a significant decline of approximately 34.3%[33] - Operating cash flow for Q1 2023 was negative at -¥19,892,433.69, contrasting with a positive cash flow of ¥29,708,153.56 in Q1 2022[48] - The total cash and cash equivalents at the end of the period stood at $126.19 million, down from $15.76 million previously[51] Revenue and Sales - The average selling price of quercetin decreased by 46.88% from CNY 823,600 per ton to CNY 437,500 per ton, contributing to the revenue decline[13] - The sales revenue of Diosmin increased by 19.53% year-on-year, while the sales revenue of Berberine increased by 97.34%[14] - The total revenue for the company reached 57,997,891, representing a 76.67% increase compared to the previous period[21] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 430,779,352.64, a decrease of 2.20% compared to the end of 2022[11] - The company's total liabilities decreased to CNY 34,817,293.65 from CNY 50,225,567.49, marking a reduction of about 30.5%[35] - The total equity attributable to shareholders increased to CNY 395,962,058.99 from CNY 390,247,751.40, reflecting a growth of approximately 1.8%[35] - The company's current assets totaled CNY 356,806,508.56, down from CNY 378,983,354.45, indicating a decrease of about 5.83%[33] Commitments and Compliance - The company has confirmed that there are no ongoing litigation or arbitration matters during the reporting period[24] - The company has maintained compliance with all regulatory requirements during the reporting period[24] - The actual controller has committed to not engaging in competitive activities with the company, and this commitment is currently being fulfilled[25] - The company is committed to implementing measures to stabilize stock prices as approved by the shareholders' meeting within three years post-listing[26] Research and Development - Research and development expenses increased to CNY 3,482,350.98 in Q1 2023 from CNY 3,082,665.80 in Q1 2022, reflecting a growth of 13%[42] - The company plans to focus on market expansion and new product development in the upcoming quarters[40] - The company plans to enhance its quercetin production capacity through automation and continuous R&D efforts, which are expected to increase sales in the future[14]

证券代码：833230 证券简称：欧康医药 公告编号：2023-042 一、 说明会类型 成都欧康医药股份有限公司（以下简称"公司"）于 2023 年 4 月 13 日在北 京证券交易所指定信息披露平台（www.bse.cn）披露了《2022 年年度报告》（公 告编号：2023-016）及《2022 年年度报告摘要》（公告编号：2023-017），为方便 广大投资者更全面深入了解公司年度经营业绩的具体情况，加强与投资者的互 动交流，公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 28 日 15:00-16:00。 （二）会议召开地点 公司定于 2023 年 4 月 28 日（周五）15:00-16:00 在上海证券报官网举办 2022 年年度报告业绩说明会，本次年报业绩说明会将采用网络远程的方式举行，投资 者可登陆上海证券报官网中国证券网（https://roadshow.cnstock.com）参与本次年 报业绩说明会。 三、 参加人员 公司董事长、总经理：赵卓君先生 公司董事会秘书、财务负责人：叶丽蓉女士 公司保荐代表人：罗泽先生 成都 ...

Company Achievements and Recognition - In 2022, Chengdu Okay Pharmaceutical Co., Ltd. was awarded the title of "Little Giant" enterprise by the Ministry of Industry and Information Technology in July[5]. - The company successfully went public on the Beijing Stock Exchange on December 9, 2022[5]. - The National Medical Products Administration approved the listing application for the chemical raw material drug (Diosmin) on October 27, 2022[5]. - The company is recognized as a national high-tech enterprise and has been included in the list of national "specialized, refined, and innovative" small giant enterprises[49]. Financial Performance - The company's operating revenue for 2022 was RMB 269,435,957.14, a decrease of 10.44% compared to RMB 300,858,164.15 in 2021[30]. - The net profit attributable to shareholders for 2022 was RMB 33,662,612.94, down 19.69% from RMB 41,916,154.19 in 2021[30]. - The total assets at the end of 2022 reached RMB 440,473,318.89, an increase of 104.27% from RMB 215,629,712.12 in 2021[32]. - The total liabilities decreased by 30.14% to RMB 50,225,567.49 in 2022 from RMB 71,894,404.96 in 2021[32]. - The net assets attributable to shareholders increased by 171.50% to RMB 390,247,751.40 in 2022 from RMB 143,735,307.16 in 2021[32]. - The basic earnings per share for 2022 was 0.57, a decrease of 21.92% from 0.73 in 2021[30]. - The company's gross profit margin for 2022 was 22.51%, down from 24.30% in 2021[30]. - The company achieved total revenue of 269.44 million yuan, a decrease of 31.42 million yuan or 10.44% compared to the same period last year[52]. - Net profit was 33.66 million yuan, a decline of 8.10 million yuan or 19.40% year-on-year, primarily due to a 19.69% drop in revenue from the company's main product series[52]. Risks and Challenges - The company faces risks related to the expiration of product quality certifications, which could adversely affect its operations if not renewed[11]. - International trade environment changes could impact the company's overseas sales, particularly in developed markets like Europe, the US, and Japan[11]. - The company is exposed to risks from fluctuations in raw material supply and prices, which could significantly affect its financial performance[12]. - The company has identified potential risks related to the inability to timely digest new production capacity, which could impact economic benefits from investment projects[13]. - The company’s core product, Quercetin, may face market growth challenges if promotional efforts do not meet expectations[13]. - The company is heavily reliant on overseas markets for product sales, which poses risks if international policy or economic conditions change[118]. - The company is at risk of losing core technical personnel, which could impact production and operational efficiency[117]. Research and Development - The company has established a technical innovation system combining product R&D and technology application, focusing on the development of natural vitamin P compounds[46]. - The company has received multiple certifications including EuGMP, FSSC22000, HACCP, ISO22000, ISO9001, HALAL, and KOSHER, enhancing its market credibility[47]. - The company aims to become a global leader in the application of natural vitamin P compounds, with a focus on sustainable development and safety[45]. - The company has formed partnerships with institutions like the Chinese Academy of Sciences and universities for collaborative R&D[46]. - The company continues to focus on the development of new products and technologies, aiming to expand into domestic markets for raw pharmaceuticals, functional food ingredients, food additives, feed additives, and cosmetic raw materials[54]. - The company has a total of 27 patents, including 4 invention patents, showcasing its strong technical foundation in the plant extraction field[62]. - The company has initiated research on the production process of the EMIQ technology, which is currently in the small-scale testing phase, with the goal of developing new products and entering new markets[99]. Market and Industry Trends - In 2022, China's plant extract exports reached 3.53 billion USD, a year-on-year increase of 16.5%[57]. - The global market for plant extracts is expected to reach 59.4 billion USD by 2025, driven by increasing consumer demand for natural and healthy products[57]. - The competitive landscape of the plant extract industry in China is characterized by a low concentration of firms, with 88% of export companies earning less than 1 million USD[60]. - The company is positioned to benefit from supportive policies aimed at the health management and traditional medicine sectors, which will enhance the market for plant extracts[59]. Corporate Governance and Compliance - The company has established a new corporate governance system during the reporting period[190]. - The company has implemented key internal controls related to revenue recognition to mitigate risks associated with improper revenue reporting[102]. - The company has conducted thorough audits of its inventory measurement processes to ensure accuracy and compliance with accounting standards[104]. - The company has committed to strict compliance with profit distribution policies and measures to address any violations of these commitments[125]. - The company has established a mechanism to ensure equal rights and protection for all shareholders[192]. Future Plans and Investments - The company plans to expand its domestic market by developing raw materials for pharmaceuticals, functional food ingredients, and food additives[113]. - The company has established a subsidiary in the United States to develop new products and facilitate cross-border e-commerce sales[113]. - The company plans to publicly issue shares to unspecified qualified investors and list on the Beijing Stock Exchange[199]. - The company plans to use the raised funds for technical transformation projects, working capital supplementation, and repayment of bank loans[147]. - The technical transformation project in Chengdu is expected to enhance production capacity[147]. Employee and Management - The company has a total of 53,484,865 shares held by directors, supervisors, and senior management, representing 70.70% of the total shares[160]. - The total number of employees increased from 206 to 208, with a net addition of 2 employees during the reporting period[167][168]. - The employee compensation policy includes regular adjustments based on performance evaluations and annual assessments[169]. - The company emphasizes training and development for employees to enhance their skills and performance[169]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility, including timely tax payments and environmental protection, while providing quality services to customers[107]. - The company has implemented a strict management system for hazardous waste and chemicals, ensuring compliance with relevant laws and regulations[188]. - The company has maintained a "zero accident" safety and environmental protection policy, with increased investment in safety and environmental measures[190].

Financial Performance - The company reported a revenue of ¥274,201,797.20 for 2022, a decrease of 8.86% compared to the previous year[3]. - Net profit attributable to shareholders was ¥34,720,762.18, down 17.17% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥31,115,942.64, reflecting a decline of 22.15%[5]. - Basic earnings per share decreased to ¥0.46, a drop of 36.99% from the previous year[5]. Assets and Equity - Total assets at the end of the reporting period reached ¥442,298,206.94, an increase of 105.12% year-on-year[5]. - Shareholders' equity attributable to the company was ¥391,536,339.84, up 172.40% compared to the beginning of the year[5]. - The company issued 18,085,981 new shares in December 2022, which diluted earnings per share[7]. Impact Factors - The decline in performance was primarily due to the impact of COVID-19 and power restrictions in Chengdu during the summer[6]. Strategic Focus - The company is focusing on technological innovation and expanding new products and markets to enhance its core competitiveness[6]. Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8].